
**PATENT** 



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Box Patent Application Assistant Commissioner for Patents** Washington, D.C. 20231

## **NEW APPLICATION TRANSMITTAL**

Transmitted herewith for filing is the patent application of Inventor(s): Hong Chen and Immaculada Silos-Santiago

For (title): NT69, A Novel Nucleoside Transporter Family Member and Uses Therefor

### 1. **Type of Application**

This new application is for a(n)

	l J r r	Design (nonprovisionar)						
	[]	Design Plant						
	[]	Divisional.						
	[]	Continuation.						
	[X]	Continuation: Continuation-in-part (C-I-P).						
	[21]	Continuation-in-part (C-1-1).						
		CERTIFICATION UNDER 37						
		(When using Express Mail, the E	-					
		Express Maii Co	ertification is op	monus.)				
I hereb	y certify th	at, on the date shown below, this correspor	ndence is being:					
		M	IAILING					
[X]	•	deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents,						
		ent Application, 29 Crystal Drive, Arlingto 37 C.F.R. Section 1.8(a)	on, VA 22202.	37 C.F.R. Section 1.10*				
	•	57 C.F.R. Section 1.6(a)		37 C.P.R. Section 1.10				
[]	with suf	ficient postage as first class mail.	[X]	as "Express Mail Post Office to Address"				
				Mailing Label No. <u>EL791760507US</u>				
				(mandatory)				
				h - ,				
Date: _	Decemb	<u>er 17, 2001</u>		Ti M				
			Signat					
			<del></del>	Ryan Severson				
				(type or print name of person certifying)				
*WAR	VING:	Each paper or fee filed by "Express Mail	!" <b>must</b> have the	number of the "Express Mail" mailing label placed				
		thereon prior to mailing. 37 C.F.R. Secti						
				without the Express Mail mailing label thereon is				
		an oversight that can be avoided by the $\epsilon$	exercise of reaso	onable care, requests for waiver of this requirement				

will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

2.	Benefit of Prior U.S. Application(s) (35 U.S.C. Sections 119(e), 120, or 121)
	[X] The new application being transmitted claims the benefit of prior U.S. Patent Application Number 09/712,797 filed November 14, 2000.
3.	Maintenance of Copendency of Prior Application
	A. [ ] Extension of time in prior application
	<b>B.</b> [ ] Conditional Petition for Extension of Time in Prior Application
	(complete this item, if previous item not applicable)
	[ ] A conditional petition for extension of time is being filed in the pending <b>prior</b> application.
	[ ] A copy of the conditional petition filed in the prior application is attached.
4.	Abandonment of Prior Application (if applicable)
	[ ] Please abandon the prior application at a time while the prior application is pending, or when the petition for extension of time or to revive in that application is granted, and when this application is granted a filing date, so as to make this application copending with said prior application.
5.	Papers Enclosed
	Required for Filing Date under 37 C.F.R. Section 1.53(b) (Regular) or 37 C.F.R. Section 1.153 (Design) Application
	91 Pages of Specification, including 87 Pages of Description 04 Pages of Claims
	01 Page of Abstract 07 Sheets of Drawings (Figures 1A-1B, 2, 3A-3B, 4, 5, 6)

	6.	Additional Papers Enclosed				
		[ ] [ ] [ X]	Information Disclosure Statement (37 C.F.R. Section 1.98) Form PTO-1449 (PTO/SB/08A and 08B) Citations Declaration of Biological Deposit 7 pages of paper copy of Sequence Listing (37 CFR Section 1.821-1.823), Diskette containing computer readable form of Sequence Listing (37 CFR Section 1.821(e) and 1.824) and 1 page of Transmittal Letter for Diskette containing computer readable form of Sequence Listing (37 CFR Section 1.821(f)) Authorization of Attorney(s) to Accept and Follow Instructions from Representative Special Comments Other:			
	7.	Declaration or Oath (including power of attorney)				
		[X]	(3 pages) An unexecuted Combined Declaration and Power of Attorney, a copy of which is enclosed.			
:		[]	Not Enclosed.			
	8.	Assig	nment			
		[X]	An assignment of the invention to Millennium Pharmaceuticals, Inc. a copy of which			
:			[ ] is enclosed. [X] will follow.			

### 9. Fee Calculation (37 C.F.R. Section 1.16)

#### A. Regular application [X]

		CLAIM	S AS FILED	<del></del>	
Claims	Numbered Filed	Basic Fee Allowance	Number Extra	Rate	Basic Fee 37 C.F.R Section 1.16(a) \$740.00
Total Claims (37 C.F.R. Section 1.16 (c))	25	- 20 = 5	х	\$18.00	90.00
Independent Claims (37 C.F.R. Section 1.16(b))	10	- 3=7	х	\$588.00	588
Multiple Dependent Claim(s), if any (37 C.F.R. Section 1.16(d))  Ame	0	+ 280.00			0

[] Amendment cancelling extra claims is enclosed.

Amendment deleting multiple-dependencies is enclosed. []

[] Fee for extra claims is not being paid at this time.

-

£ &

Filing Fee Calculation

\$1,418.00

10.	Meth	od of Payment of Fees Check in the amount of \$	·			
	[X]	Charge Account No. 501668 in the a A duplicate of this transmittal is atta				
11.	Autho	orization to Charge Additional Fees  The Commissioner is hereby author paper and during the entire pendency	rized to charge the following additional fees by this of this application to Account No. 501668.			
		[X] 37 C.F.R. Section 1.16(a), (f	or (g) (filing fees)			
		[X] 37 C.F.R. Section 1.16(b), (c	e) and (d) (presentation of extra claims)			
	[ ] 37 C.F.R. Section 1.16(e) (surcharge for filing the basic filing feed declaration on a date later than the filing date of the application)					
		[ ] 37 C.F.R. Section 1.17(a)(1)	-(5) (extension fees pursuant to Section 1.136(a).			
		[ ] 37 C.F.R. Section 1.17 (appl	37 C.F.R. Section 1.17 (application processing fees)			
		[ ] 37 C.F.R. Section 1.18 (issipursuant to 37 C.F.R. Section	ue fee at or before mailing of Notice of Allowance, n 1.311(b))			
12.	Instru [X]	ctions as to Overpayment Credit Account No. 501668.				
	[]	Refund				
			Qui E. Uhl			
			SIGNATURE OF PRACTITIONER			
			Jill E. Uhl, Reg. No. 43,213			
			(type or print name of practitioner)			
			Millennium Pharmaceuticals, Inc. P.O. Address			
			75 Sidney Street			
			Cambridge, MA 02139			
			Telephone (617) 551-3969			
[X]	Staten	nent Where No Further Pages Added	Facsimile: (617) 551-8820			
	[X]	This transmittal ends with this page.				

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Honh Chen et al.

Serial No.: N/A

Filed: Herewith

For: NT69, A Novel Nucleoside Transporter Family

Member and Uses Therefor

Attorney Docket No.: MPI2000-433CP1(M)

**Assistant Commissioner for Patents** Box Sequence Washington, D.C. 20231

# TRANSMITTAL LETTER FOR DISKETTE CONTAINING COMPUTER READABLE FORM OF SEQUENCE LISTING

Dear Sir:

Enclosed is a diskette which contains a computer readable form of the Sequence Listing for the patent application filed herewith. The Sequence Listing complies with the requirements of 37 C.F.R. § 1.821. The material on this diskette is identical in substance to the Sequence Listing which is submitted herewith, as required by 37 C.F.R. § 1.821(f). The computer readable form of the sequence listing contained on the enclosed diskette is understood to comply with the requirements of § 1.824(d).

Express Mail" mailing label numberEL791760507US			
Date of Deposit December 17, 2001			
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box Sequence, 2900 Crystal Drive, Arlington, VA 22202			
Signature			
Ryan Severson			
Please Print Name of Person Signing			

MILLENNIUM PHARMACEUTICALS, INC.

Registration No.: 43,213 Attorney for Applicant

Millennium Pharmaceuticals, Inc.

75 Sidney Street

Cambridge, MA 02139 Telephone: 617-551-3969 Facsimile: 617-551-8820